FDA-approved oral AML therapy could let older patients avoid monthly infusion visits

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires ...
ascopubs.org

Real-World Outcomes of Hypomethylating Agents and Venetoclax Combination Therapy in AML and Myelodysplastic Syndrome in Pakistan

The combination of venetoclax (VEN) and a hypomethylating agent (HMA) is a standard of care for patients with AML and higher-risk myelodysplastic syndromes (MDS). However, real-world outcomes data ...